| Business Summary | | Shire
Pharmaceuticals
Group
PLC
is
an
international
specialty
pharmaceutical
company
with
a
strategic
focus
on
four
therapeutic
areas:
central
nervous
system
disorders,
metabolic
diseases,
oncology
and
gastroenterology.
The
Company
operates
and
manages
its
business
in
the
United
States,
Europe
and
the
rest
of
the
world.
Within
these
geographical
segments,
revenues
are
derived
from
sales
of
products
by
the
Company's
own
sales
and
marketing
operations,
licensing
and
development
fees
and
royalties.
Shire
Pharmaceuticals
has
its
own
direct
marketing
capability
in
the
United
States,
Canada,
the
United
Kingdom,
the
Republic
of
Ireland,
France,
Germany,
Italy
and
Spain.
The
Company
also
covers
other
pharmaceutical
markets
indirectly
through
distributors. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | SHPGY
is
a
specialty
pharmaceutical
company
focused
on
four
therapeutic
areas:
central
nervous
system
disorders,
metabolic
diseases,
cancer
and
gastrointestinal
disorders.
For
the
six
months
ended
6/30/01,
revenues
rose
29%
to
$400.6
million.
Net
loss
totaled
$82.7
million
vs.
an
income
of
$141.2
million.
Revenues
reflect
an
increased
share
of
the
U.S.
ADHD
market.
Net
loss
reflects
$177
million
in
charges
related
to
the
Biochem
merger. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| James Cavanaugh, 63 Chairman | -- | Rolf Stahel, 56 CEO,
Director | $971K | Angus Charles Russell, 44 Director,
CFO | 456K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|